Aceclidine and Tropicamide Presbyopia Treatment Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for presbyopia, such as miotic agents, often cause significant side effects like diminished distance vision, blurred vision, pain, redness, nasal congestion, and risk of retinal detachment, and require invasive methods or cycloplegic agents, which are inefficient and have stability issues.
Innovation Solution
A composition comprising a muscarinic agonist that preferentially activates M1 and M3 muscarinic acetylcholine receptors, specifically aceclidine, is used to treat presbyopia, with a cycloplegic agent like tropicamide at low concentrations to reduce side effects and enhance depth of focus without ciliary spasms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If general miotic agents (pilocarpine, carbachol, phospholine iodide) are used to treat presbyopia, then near vision is improved through increased ciliary muscle contraction and pinhole effect, but distance vision deteriorates due to induced myopia and significant side effects occur including redness, nasal congestion, and ciliary muscle spasms
Solution Approach 1:
The patent segments the muscarinic receptor system into specific subtypes (M1 and M3) and develops aceclidine to selectively target these receptors. This segmentation allows the drug to achieve the desired ciliary muscle contraction for near vision improvement while avoiding excessive accommodation that causes distance vision deterioration and side effects like redness and nasal congestion.
Solution Approach 2:
The patent changes the pharmacological parameters by developing aceclidine with specific selectivity ratios for M1 versus M3 receptors. By optimizing these receptor binding parameters, the drug achieves effective presbyopia treatment with reduced induced myopia and minimized side effects compared to non-selective miotics.
2Object-affected harmful factors
If cycloplegic agents are combined with miotic agents to reduce side effects, then ciliary spasms and redness are reduced, but the formulation complexity increases and stability issues arise
Solution Approach 1:
The patent introduces a cycloplegic agent as an intermediary substance that counteracts the excessive ciliary muscle contraction caused by miotic agents. This intermediary action reduces ciliary spasms and associated redness while maintaining the therapeutic benefits for near vision, effectively mediating between the miotic effect and side effect reduction.
3Manufacturing precision
If aceclidine is formulated for commercial use, then presbyopia treatment effectiveness is improved with selective M1/M3 activation, but formulation stability becomes a critical challenge
Solution Approach 1:
The patent develops composite formulations that combine aceclidine with specific excipients and stabilizing agents. This composite approach maintains the pharmacological integrity and receptor selectivity of aceclidine while addressing formulation stability challenges for commercial use, creating a stable pharmaceutical product that preserves the drug's therapeutic properties.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides improved near vision with minimal impact on distance vision, reducing side effects like redness and ciliary spasms, and stabilizes aceclidine compositions for commercial use, allowing for prolonged and effective treatment without the need for invasive methods.
Implementation Method 1
A composition comprising a muscarinic agonist that preferentially activates M1 and M3 muscarinic acetylcholine receptors, specifically aceclidine, is used to treat presbyopia
Implementation Method 2
with a cycloplegic agent like tropicamide at low concentrations to reduce side effects and enhance depth of focus without ciliary spasms
Data Source
AI summary
The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a cycloplegic agent. The compositions optionally contain a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.